Lina Asmar

9.2k total citations
169 papers, 6.4k citations indexed

About

Lina Asmar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Lina Asmar has authored 169 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 87 papers in Pulmonary and Respiratory Medicine and 53 papers in Cancer Research. Recurrent topics in Lina Asmar's work include Cancer Treatment and Pharmacology (68 papers), Breast Cancer Treatment Studies (43 papers) and Lung Cancer Treatments and Mutations (32 papers). Lina Asmar is often cited by papers focused on Cancer Treatment and Pharmacology (68 papers), Breast Cancer Treatment Studies (43 papers) and Lung Cancer Treatments and Mutations (32 papers). Lina Asmar collaborates with scholars based in United States, United Kingdom and Canada. Lina Asmar's co-authors include Kristi A. Boehm, Aman U. Buzdar, Gabriel N. Hortobágyi, Harold M. Maurer, William A. Newton, Richard L. Theriault, Frankie A. Holmes, Ala B. Hamoudi, Shaker R. Dakhil and Svetislava J. Vukelja and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Lina Asmar

168 papers receiving 6.2k citations

Peers

Countries citing papers authored by Lina Asmar

Since Specialization

Citations

This map shows the geographic impact of Lina Asmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lina Asmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lina Asmar more than expected).

Fields of papers citing papers by Lina Asmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lina Asmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lina Asmar. The network helps show where Lina Asmar may publish in the future.

Co-authorship network of co-authors of Lina Asmar

This figure shows the co-authorship network connecting the top 25 collaborators of Lina Asmar. A scholar is included among the top collaborators of Lina Asmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lina Asmar. Lina Asmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial 2013 ·Investigational New Drugs ·Craig H. Reynolds, Alexander I. Spira, (unknown), (unknown), Zhan Feng, Kristi A. Boehm, Lina Asmar	12
2	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial 2011 ·The Lancet ·Cornelis JH van de Velde, Daniel Rea, Caroline Seynaeve, Hein Putter, Annette Hasenburg, Jean-Michel Vannetzel, Robert Paridaens, Christos Markopoulos, Yasuo Hozumi, E.T.M. Hille, D. G. Kieback, Lina Asmar, Jan Smeets, J.W.R. Nortier, Peyman Hadji, John M.S. Bartlett, Stephen E. Jones	264
3	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer 2011 ·Clinical Colorectal Cancer ·Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil, (unknown), W G Harker, (unknown), (unknown), (unknown), Paul Conkling, Mark Allen O’Rourke, Donald Richards, Diane Reidy‐Lagunes, David B. Solit, Efsevia Vakiani, (unknown), (unknown), Zhan Feng, Kristi A. Boehm, Lina Asmar, Allen Lee Cohn	58
4	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 2009 ·Journal of Clinical Oncology ·Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi McIntyre, John Pippen, (unknown), Robert Kirby, John F. Sandbach, William Hyman, Donald Richards, Robert Mennel, Kristi A. Boehm, Wally Meyer, Lina Asmar, Daniel Mackey, Stefan Riedel, Hyman B. Muss, Michael A. Savin	400
5	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy 2009 ·Annals of Oncology ·Guru Sonpavde, Phillip Periman, (unknown), Douglas Weckstein, Mark T. Fleming, Matthew D. Galsky, William R. Berry, Feng Zhan, Kristi A. Boehm, Lina Asmar, Thomas E. Hutson	115
6	Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Craig H. Reynolds, (unknown), Robert M. Jotte, Alexander I. Spira, Charles Weissman, Kristi A. Boehm, (unknown), Lina Asmar	46
7	Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer 2009 ·Breast Cancer Research and Treatment ·John W. Smith, Kristi McIntyre, (unknown), Carlos A. Encarnacion, Karen L. Tedesco, Yunfei Wang, Lina Asmar, Joyce O’Shaughnessy	14
8	The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer 2008 ·Clinical Breast Cancer ·Stephen E. Jones, Christopher Stokoe, Mark D. Sborov, (unknown), (unknown), Leila A. Kutteh, John Pippen, (unknown), Devchand Paul, Joanne L. Blum, Frankie A. Holmes, (unknown), James Cantrell, (unknown), (unknown), E. Di Salle, Jennifer C. Davis, D. Ilegbodu, Lina Asmar	20
9	Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy 2007 ·Clinical Genitourinary Cancer ·Guru Sonpavde, Ana M. Aparicio, (unknown), Kristi A. Boehm, Thomas E. Hutson, William R. Berry, Lina Asmar, Daniel D. Von Hoff	11
10	P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Craig H. Reynolds, Paul Conkling, Donald Richards, James F. Fitzgibbons, James C. Arseneau, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Coleman K. Obasaju	3
11	Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer 2006 ·Journal of Clinical Oncology ·Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh, Kathy S. Albain, (unknown), Lea Fuchs, Dennis J. Slamon	342
12	Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials 2004 ·Lung Cancer ·Thomas Marsland, (unknown), Myrna M. Khan, (unknown), Kristi A. Boehm, Lina Asmar	23
13	Phase II Randomized Trial of Weekly Paclitaxel with or Without Estramustine Phosphate in Progressive, Metastatic, Hormone-Refractory Prostate Cancer 2004 ·PubMed ·William R. Berry, James W. Hathorn, Shaker R. Dakhil, David Loesch, Don V. Jackson, Mary Ann Gregurich, (unknown), Lina Asmar	35
14	A Phase II Evaluation of Weekly Paclitaxel Plus Carboplatin in Advanced Urothelial Cancer 2004 ·Cancer Investigation ·David Friedland, Shaker R. Dakhil, (unknown), Mary Ann Gregurich, Lina Asmar	12
15	Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up 2000 ·Annals of Oncology ·Nuhad K. Ibrahim, Aman U. Buzdar, Lina Asmar, Richard L. Theriault, Gabriel N. Hortobágyi	45
16	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center 1997 ·Cancer Chemotherapy and Pharmacology ·Naoto T. Ueno, Aman U. Buzdar, S. Eva Singletary, Frederick C. Ames, Marsha D. McNeese, Frankie A. Holmes, Richard L. Theriault, Eric A. Strom, (unknown), Lina Asmar, Debbie Frye, Gabriel N. Hortobágyi	186
17	Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. 1997 ·Journal of Clinical Oncology ·R. Beverly Raney, Lina Asmar, William A. Newton, Charles E. Bagwell, John C. Breneman, W M Crist, E. A. Gehan, Bruce L. Webber, Moody D. Wharam, Eugene S. Wiener, J R Anderson, Harold M. Maurer	172
18	Hyperfractionated radiation in children with rhabdomyosarcoma—Results of an intergroup rhabdomyosarcoma pilot study 1995 ·International Journal of Radiation OncologyBiologyPhysics ·Sarah S. Donaldson, Lina Asmar, John C. Breneman, Christopher Fryer, Arvin S. Glicksman, (unknown), Moody D. Wharam, Edmund A. Gehan	38
19	Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group. 1993 ·Journal of Clinical Oncology ·Alberto S. Pappo, W M Crist, John F. Kuttesch, Susan Rowe, Richard A. Ashmun, Harold M. Maurer, William A. Newton, Lina Asmar, Xi Luo, David N. Shapiro	26
20	Spindle Cell Variants of Embryonal Rhabdomyosarcoma in the Paratesticular Region 1993 ·The American Journal of Surgical Pathology ·Ivo Leuschner, William A. Newton, Dietmar Schmidt, (unknown), Lina Asmar, Ala B. Hamoudi, (unknown), Harold M. Maurer	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact